Senior Worldfirst Executive Joins UK Fintech Storfund
After a six month search, Storfund has appointed Worldfirst’s former Global Head of Enterprise, Oliver Whelan, as its Chief Revenue Officer. Whelan, who spent almost a decade at payments fintech Worldfirst, will be responsible for accelerating Storfund’s rapid and profitable growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005094/en/
Oliver Whelan, Chief Revenue Officer (Photo: Business Wire)
Available in 20 countries on the world’s biggest marketplaces, including Cdiscount, Back Market, PcComponentes, Fyndiq and Amazon, Storfund is one of the UK’s fastest growing fintechs. But what’s more remarkable in an industry obsessed with scaling loss-making operations, Storfund has achieved this growth whilst turning a profit.
The founders took the decision to fund growth from revenue rather than external capital, believing this would create an impact-driven culture: growth would only come if clients saw that its service was worth paying for.
“Unlike its competitors, Storfund has focused on its product and, most importantly, its customers” said Whelan, “it knows why it exists and it hasn’t forgotten this in the pursuit of growth.” Storfund is the only European provider of factoring - immediate payment on sales - to marketplace sellers, an essential service given businesses wait 42 days on average to get paid.
“Cashflow remains the biggest challenge for ecommerce businesses,” said Whelan. “There are a few start-ups offering loans to ecommerce sellers, but Storfund is still the only European fintech to offer working capital in the form of factoring. Traditional banks, even digital challenger banks, still don’t understand the ecommerce sector.”
“Storfund’s potential is immense” said Whelan, “it is offering a simple solution to an industry worth almost £4 trillion.”
Demand for its service means that Storfund has doubled the financing it provides every year for the past three years; and last autumn Storfund announced that it had put in place financing which would enable it to provide up to £5 billion each year to ecommerce businesses. Whelan’s task will be to capitalise on this momentum, drawing on his experience at Worldfirst.
Worldfirst’s breakneck growth saw it transfer over £70 billion for customers between its launch in 2004 and 2019 when it was acquired by Ant Group, in one of the largest deals by the world’s largest fintech. As Wordfirst’s Global Head of Enterprise, Whelan was responsible for negotiating the business’s largest strategic ecommerce and financial partnerships.
“Worldfirst’s success was driven by its culture,” said Whelan, “and Storfund is the same. It has a fantastic team and loyal, enthusiastic customers – over a third of new business comes from recommendations”.
“The strength of our product, our funding structure and obsession with profitable growth enables us to stay 100% focused on our mission, said George Brintalos, CEO and co-founder, “it’s also one of the reasons we are able to attract exceptional talent like Oliver and continue to hire whilst the industry as a whole is retrenching.”
The tech industry has been awash with venture capital over the past three years, and Storfund’s unusual decision not to take external capital puts it in a strong position to weather the market downturn, which has particularly affected the value of tech businesses. Without the pressure for returns, Storfund is well placed to continue growing via steady expansion.
The next few years will be all about expansion through partnerships with fast-growing marketplaces across Europe, Asia and the Americas. “Oliver is the right person at the right time,” said Akbar Ahsan, co-founder, “not only does he have an enviable track record and a vast network, he’s also the right cultural fit. He has an entrepreneurial mindset and gets our mentality of rolling your sleeves up and getting stuck-in, but he also brings the discipline and process-driven thinking that large corporations instil, which will be crucial as our international operations expand even further.”
Whelan’s appointment follows Storfund’s strategy of appointing experienced ecommerce executives to senior roles. Other notable hires include David Rolls from Amazon and Margaret-Anne Galvin from Cdiscount.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Contact Hana Graham, Head of Marketing at Storfund on email@example.com or 00 44 7812 011756 for additional information, assets and interviews.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Unveils Nourish Innovation Lab in Union Beach, New Jersey19.8.2022 12:55:00 CEST | Press release
IFF (NYSE:IFF) today announced the opening of its new Nourish Innovation Lab at the company’s Union Beach, New Jersey research and development center. In the state-of-the-art lab, scientists—including flavorists and food designers—will leverage tools, technologies and ingredient expertise to offer customers full product design, driving growth in the global food and beverage markets by fast forwarding innovation. “This new facility is a testament to how we pioneer innovation and drive speed to market and accessibility to our customers,” said Nicolas Mirzayantz, president of Nourish, IFF. “We will nurture an innovation project from concept to kitchen table, under one roof. Using our scientific knowhow, application excellence and full portfolio of ingredients, we’ll improve the taste and nutrition profiles of next-generation food and beverages. With our new culinary kitchen, we’re enabling technology focused on the consumer-eating experience, taking food development out of the traditional
PUMA Ambassador and European Champion Gianmarco Tamberi Talks “Only See Great”19.8.2022 11:52:00 CEST | Press release
Six years after his first gold medal, Tamberi takes back the European title and speaks about his motivation to keep performing at the highest level in a video interview with sports company PUMA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220819005125/en/ Six years after his first gold medal, Tamberi takes back the European title and speaks about his motivation to keep performing at the highest level in a video interview with sports company PUMA. (Photo: Business Wire) With the ‘Only See Great’ campaign, PUMA explores the career path of its brand ambassadors, as they talk about their own pursuit of greatness, listening to their hearts, and finding a vision that no one else can see. In the interview, Gianmarco talks about his very first successes and extraordinary performance at the Olympic Games in Tokyo. “That feeling that I had that day, that happiness I couldn’t even imagine that could exist. It’s something that was co
Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)19.8.2022 10:30:00 CEST | Press release
Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the European Commission (EC) approved CRYSVITA® (burosumab) for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed in the EU for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with fewer than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with progressive and debilitating musculoskeletal deficits,6,7 ultimately having a detr
Kapruvia ® approved in Switzerland with additional regulatory decisions expected in H2 202219.8.2022 07:00:00 CEST | Press release
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by the U.S. Food and Drug Administration, by the European Medicines Agency, by the UK Medicines and Healthcare products Regulatory Agency, as well as by Health Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005552/en/ “The approval of Kapruvia® in Switzerland is the next step on our journey to bring this breakthrough treatment to hemodialysis patients living with CKD-associated pruritus around the world,” said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “There is a
European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer19.8.2022 04:47:00 CEST | Press release
Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma™ (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin®, for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer. “The European Commission’s approval of Vegzelma™ will increase access to treatment for patients living with certain types of cancer at an affordable price,” said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare. “With proven similarities in efficacy and safety compared to the reference product Avastin®, Vegzelma™ will be available to treat some of the most commonly diagnosed cancers, which collectively affect hundreds of thousands of European patients each year.” The EC approval of Vegzelma™ follows the recommendation for marketing authorisation issued by the Committee for Medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom